Hierridin C Antimalarial Agent Against Resistant Plasmodium
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial drugs face challenges due to emerging drug-resistant strains of Plasmodium falciparum, particularly mefloquine and chloroquine-resistant strains, necessitating the development of new agents effective against resistant parasites.
Innovation Solution
The use of hierridin C, a halogenated alkyl-aromatic secondary metabolite isolated from Cyanobium sp. LEGE 06113, which demonstrates antimalarial activity against both sensitive and resistant strains of P. falciparum, including the multidrug-resistant Dd2 strain, and can be obtained through laboratory cultures or chemical synthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antimalarial drugs (chloroquine, mefloquine) are used, then treatment of malaria is effective against sensitive strains, but drug-resistant strains emerge and reduce treatment efficacy
Solution Approach 1:
The patent applies parameter changes by introducing a novel chemical structure class (halogenated alkyl-aromatic secondary metabolites) with different physicochemical properties compared to existing antimalarials. Hierridin C features a unique molecular framework with halogen substitution, alkyl chains, and aromatic rings, representing a significant structural parameter change that enables activity against resistant strains while maintaining efficacy against sensitive parasites
2Reliability
If new antimalarial agents are developed to combat resistant strains, then activity against resistant parasites is improved, but potential cytotoxicity to human cells may increase
Solution Approach 1:
The patent applies local quality by optimizing specific regions of the hierridin C molecule. The structure contains distinct functional zones: the halogenated aromatic core provides antimalarial activity, while the alkyl chain length and methoxy group positions are carefully positioned to enhance selectivity. This localized optimization allows potent activity against resistant P. falciparum while minimizing off-target effects on human cells
Solution Approach 2:
The patent employs structure-activity relationship analysis to identify minimal effective structures. By determining the essential structural features required for activity against resistant strains, the invention focuses on the core halogenated aromatic framework with specific substituents, eliminating unnecessary molecular complexity that could increase cytotoxicity while maintaining therapeutic efficacy
Data Source
Figure 1A~1B
Figure 2
Figure 3~5
AI summary
The present disclosure relates to compound of the formula I wherein R1 is a halogen; R2, R4 are independently selected from a group consisting of C1–C6 alkyl, H, COCH3, COH, CO-alkyl, CO-aryl; R3 is a C3–C30 alkyl; or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, for use in medicine, in particular as antimalarial agent. The present solution relates to halogenated alkyl-aromatic secondary metabolites, in particular hierridin C from the cyanobacterium Cyanobium sp. LEGE 06113 - which was received on 29 May 2015 and accepted for deposit for patent purposes on 15th June 2015 at the Scottish Association for Marine Science Culture Collection of Algae and Protozoa (CCAP) - International Depositary Authority under the Budapest Treaty - under the CCAP number 1436/1- and its application as an antimalarial agent.